

Special Issue

Clinical Trials and Outcomes for Non-Small Cell Lung Cancer

Message from the Guest Editors

Non-Small Cell Lung Cancer (NSCLC) treatment has changed dramatically in the last 2.5 decades. We evolved from an armamentarium that was limited to surgery, radiotherapy and chemotherapy, chosen according to the histologic subtype, to the integration of these with target therapies, immunotherapy, and combination of different systemic treatments, according to the presence of actionable oncogenic alterations and other biomarkers. The aim of this issue is to divulgate and integrate clinical trials and outcomes in the knowledge of NSCLC treatment, specially translating these results for our daily practice. We are pleased to invite you to collaborate with us. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: clinical trials, real world data and reviews. We look forward to receiving your contributions.

Guest Editors

Dr. Ana Rodrigues

Medical Oncology Department, Research Center Cancer Biology & Epigenetics Group and Clinical Trials Department, Instituto Português de Oncologia do Porto (IPO-Porto), Porto, Portugal

Prof. Dr. António Araújo

1. Centro Hospitalar Universitário do Porto, Porto, Portugal
2. Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal

Deadline for manuscript submissions

31 January 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/229356

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)